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1. Introduction 
Atopic dermatitis (AD) is a chronic, relapsing and pruritic inflammatory skin disorder. The 
prevalence of AD has been increasing significantly in recent decades, especially in 
developed nations. The pathogenesis of AD is still not completely understood. AD may be 
the results of interactions of abnormalities of immune system, genetics, environment and 
epidermal barrier defects. There is a wide spectrum of clinical manifestations in AD. 
Accordingly, there have been a number of methods and laboratory markers to assess the 
severity of AD. In spite of the facts that various severity assessing criteria and laboratory 
markers were reported or, more or less, applied, owing to the complexity of disease, race 
differences and environmental uncertainties, there is disagreement about the definitions and 
clinical application of these criteria or markers. Nevertheless, easy and quick assessing 
severity methods for AD are required to guide both the daily clinical and research studies. 
Here, we describe some recent advances in the assessment of the severity of AD. 
1.1 Overview of the epidemiology of AD 
AD is a chronic, inflammatory, itchy condition that usually begins in infancy but may 
continue into adult life; the disease is genetically predisposed, and its expression is modified 
by environmental factors. The prevalence of AD is unevenly distributed worldwide, varying 
between 0.73-23% (Levy et al., 2003).There is a tendency of increased prevalence of AD in 
recent years, especially in developed industrial nations. For example, the prevalence of AD 
at the ages of 12-15 almost doubled in the last 20 years of 20th century in Japanese, 
suggesting the strong impact of environmental factors in AD development(Sugiura et al., 
1998).The incidence of an infant to develop AD is 25% in three months after birth, or 50% in 
two years after birth, given that the mother is an AD sufferer; The incidence of AD in the 
offspring reaches as high as 79%, if both the parents are atopic patients, suggesting the key 
role of genetic predisposition in the pathogenesis of AD(Bradley er al., 2000).Key clinical 
manifestations of AD include itchy, dry skin, inflammatory rashes and other atopic 
conditions. Though not fully clarified, the clinical phenotype characterizing AD is the 
product of interactions between susceptibility genes, the environment, defective skin barrier 
function, and immunologic responses. These complex interactions would induce biological 
and immunological responses at cellular or molecular levels, involving the skin, immune 
system or even the integument as a whole.  
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1.2 Diagnostic criteria of AD  
During the past decades about 10 diagnostic criteria for AD have been set 
up(Brenninkmeijer et al., 2008),while the Hanifin and Rajka diagnostic criteria(in 1980) and 
Williams diagnostic criteria(in 1994) are the two most widely used methods in the 
world(Roguedas et al., 2004)．The H-R criteria is such a detailed one (4 major and 23 minor 
criteria) that it is time consuming and not easy to operate, and thus mainly suitable for 
investigative studies and impractical for epidemiologic studies. What’s more, some of the 
minor features described in the criteria, such as anterior neck folds and the Dennie-Morgan 
infra-orbital fold, has been challenged for their diagnostic significance in a study on Swiss 
AD (Mevorah et al., 1988). The concise Williams criteria (1 mandatory and 5 major criteria), 
are suitable for clinical and epidemiological studies. Williams criteria has been extensively 
validated(Brenninkmeijer et al., 2008). Due to its inherent nature of easy operation, this 
diagnostic criterion could be recommended in future international studies. In 1995, 
International Study of Asthma and Allergies in Childhood (ISAAC) set up ISAAC 
questionnaire for prevalence survey of childhood AD(Asher et al., 1995).Taken together, an 
ideal diagnostic criteria need to be well-validated ,easy to apply and suitable for 
interventional multicenter trials. 
2. Assessment of the disease severity in AD 
The methods of measuring disease severity of AD include the evaluation of lesion 
manifestations in combination with disease extent and intensity, subjective symptoms, 
quality of life (QOL), and the assessment of skin barrier function by bioengineering methods 
and laboratory parameters. 
2.1 Assessment of clinical scoring systems 
In the past, assessing the severity of AD, at levels of either overall or individual parameters, 
was mostly dependant on clinical scoring systems, such as the Scoring Atopic Dermatitis 
index (SCORAD)( European Task Force on Atopic Dermatitis, 1993), Atopic Dermatitis 
Area and Severity Index score(ADASIS) (Bahmer, 1992), Eczema Area and Severity Index 
(EASI) (Hanifin, 2001), are the most widespread used methods, to name a few(Charman 
&Williams, 2000).All of these tools, based on the entirely subjective score, have considerable 
inter-observer variability owing to the observers bias. 
ADASIS was based on the lesion areas by point counting. On special body diagrams, the 
areas were color coded according to the severity of inflammation (green for mild, blue for 
moderate, and red for severe dermatitis).The result was evaluated by applying a 
transparent grid and fractionated lesion areas were weighted and multiplied by subjective 
pruritus intensity score. Haniffin et al suggested EASI index to assess the disease extent 
and percents of lesion area in four body regions (head and neck, lower limbs, upper limbs 
and trunk), borrowed from the psoriasis area and severity index (PASI) (Hanifin, 2001). 
The study by Rullo et al informed that EASI is more suitable for detection of subtle 
alterations of the severity of AD during drug effect studies, or follow-up of progression 
for research purposes (Rullo, 2008). 
Charman and Williams evaluated 13 AD clinical scoring systems and confirmed that the 
simple and rapid SCORAD index was the most widely used one and its validity, reliability, 
sensitivity, and acceptability have been widely confirmed(Charman &Williams, 2000).The 
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SCORAD index includes objective symptoms (extent and intensity) and subjective criteria 
(daytime pruritus and sleep loss). The severity assessment of each items were evaluated at 
its average intensity. Due to that the subjective symptoms represented 20 % of total of inter-
observer variation, European Task Force on Atopic Dermatitis recommended severity scale 
based only on the objective criteria of the SCORAD index to define mild, moderate, and 
severe AD (Kunz, 1997). It remains to be investigated that quite some laboratory parameters 
obtained from the lesion, serum, and other body fluids, have no significant correlation with 
SCORAD index. SCORAD index can not reflex the whole aspects of AD. 
Most of the severity index has been applied for a given short-term therapeutic intervention, 
while they are insensitive in reflecting the overall disease activity to the chronic and 
fluctuating course of AD. Nottingham Eczema Severity Score (NESS) was introduced to be a 
clinical severity score method that documents AD severity over a long -term period of 12 
months(Emerson et al., 2000; Hon et al., 2006).  
For evaluating the life quality in AD, Quality of Life Index for Atopic Dermatitis (QoLIAD) 
is designed for adults with AD based on Quality of Life (QoL)and Children's Dermatology 
Life Quality Index (CDLQI) for children AD. These instruments could be used to evaluate 
the impact degree of AD and also measure the therapeutic effect (Whalley et al., 2004; Ben-
Gashir et al., 2004). 
Taken together, though well recognized and widely applied, the implementation of various 
scoring systems is complicated and subject to a variety of bias. Noninvasive, objective 
measurement has been developed and in use in recent year. The objective severity 
assessment of atopic dermatitis system (OSAAD) (Sugarman et al., 2003), which take 
advantage of instrumentations to measure water content (stratum corneum hydration, 
SCH), sebum content and trans-epidermal water loss (TEWL) of the skin, features the recent 
development of objective evaluation of AD. 
OSAAD is a severity evaluation scale in AD including TEWL, SCH using a noninvasive 
bioengineering methods and estimation of affected body surface area (BSA). The method 
is suitable for both children and adults with AD compared with classical scoring system 
(Angelova-Fischer et al., 2005). The OSAAD score have several advantages over the 
clinical scoring methods. Measurement of TEWL and SCH is reproducible and reliable 
under given standard environment condition and instrument devices(Angelova-Fischer et 
al., 2005), able to evaluate quantitatively the severity scale of skin barrier impairment, 
sensitive to minor fluctuations in the course of AD development, and consequently 
applicable to assessment of treatment effects. The limitations of this technique are the 
inter- or intra- variability in AD patients, influenced by anatomic sites, environmental 
changes, etc. So the standardization of the conditions is very important in multicenter 
trials .There is no unified standard sites suitable for evaluation. Choi et al showed that 
antecubital fossa is the most favorable site for TEWL evaluation (Choi et al., 2003), while 
flexure surface is unsmooth. The ‘2 cm’ site under the antecubital fossa resembles a 
flexure and is conveniently flat for measurements (Hon et al., 2008). 
2.2 Evaluation of skin function and properties 
The skin barrier is primarily in the outer 15μm of the epidermis, the stratum corneum (SC) 
(Landmann, 1988). Breakdown of skin barrier is the primary event in the development of 
AD, which may result in atopic march (Lipozencic & Wolf, 2007) . The evaluation of skin 
barrier and properties is based on several variances: such as TEWL, natural moisturizing 
factors (NMF), skin sebum content, skin pH and skin hydration (SH). The study 
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environment (controlled temperature and humidity level) of bioengineering research 
should be standardized.  
From the skin surface, SH is relatively difficult to quantify objectively, instead, SCH level is 
measured .TEWL is a method to reflex SH, and also correlated well with objective SCORAD 
score (Gupta et al., 2008).There are two main systems which have been used to measure 
TEWL by comparing water flux rate following titrated water application: open chamber and 
closed chamber. The main drawback of open-chamber systems is the disturbance of air 
movements. The closed-chamber systems conquers this limitation by its closed-chamber, but 
a major problem with it is that it can not be used to perform continuous measurement, as 
there is a need of cleaning water vapor of the chamber after a site reading. Elkeeb et al 
introduced a new closed-chamber systems with a condenser to remove water vapor from 
chamber and enabling continuous measurement and confirmed significantly correlated with 
conventional closed and open-chamber systems(Elkeeb et al., 2010) .Later agreed standards 
of TEWL calibration method is needed to improve the comparability of TEWL measurement 
devices supplied by different manufacturers.  
NMF is the most important factor for maintaining the skin proper moisture levels in SC. 
NMF largely comes from the acid degradation products of filaggrin, including pyrrolidone 
carboxylic acid (PCA) and urocanic acid (UCA), which also contribute to skin hydration acid 
mantle in outer SC (O'Regan et al., 2009) .While lowered expression of FLG in AD lesion was 
found universally (Howell et al., 2009), the loss-of-function mutations of FLG were observed 
in only less one-third of the general AD population (Marenholz et al., 2006; Palmer et al., 
2006; Zhang et al., 2011; Ma et al., 2010). Reduced NMF levels were independently 
associated with FLG genotype and is a general feature of AD (Kezic et al., 2010).High-
Performance Liquid Chromatograph (HPLC) is the common method used to evaluate NMF 
(Robinson et al., 2010a; Robinson et al., 2010b ).  
The skin surface sebum content, hydration and pH can be check by several commercialized 
instruments with respective probes on the surface of skin (Choi et al., 2003; Firooz et al., 
2007; Man et al., 2009). They are easy to operate, but time consuming, difficult to use in 
infant AD patients. The temperature and humidity levels during their application also 
should be standardized. 
2.3 Laboratory tests 
Laboratory tests may also be applied for AD.  
2.3.1 Skin tests (atopy patch test/ APT, skin prick test /SPT) 
APT was traditionally used to assess sensitization to inhalant. Allergens/aeroallergen as a 
skin test, was used to diagnose AD (Ring et al., 1997).An eczematous reaction based on T 
cell–specific delayed-type allergic response to the allergens on the healthy skin of the 
patient's back or forearm is read after 48 and 72 hours. There is no golden standard for 
aeroallergen provocation of AD. Although the kinds of allergens are different in patients of 
different environment, race, and regions, the European APT model with standardization of 
allergen concentration and vehicle may be an useful diagnostic tool to AD patients. 
However, the clinical relevance of positive APT reactions depends on standardized 
provocation and avoidance testing verification (Lipozencic & Wolf, 2010). 
Although the double-blind, placebo-controlled oral food challenges (DBPCFC) is the golden 
standard of diagnosis in food allergy(Sampson, 2003).The test is not always suitable to 
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interpret and operate, particularly in patients sensitive to several kinds of food or potential 
to anaphylactic Shock. Skin prick test (SPT) is designed for diagnosing food immediate 
hypersensitivity(Isolauri & Turjanmaa, 1996).The APT reflect delayed-phase allergic 
reactions, even with a late onset of symptoms (more than 2 hours after food ingestion). APT 
may provide further diagnostic information in addition to the SPT and serum IgE values 
used with standardized allergen concentration and vehicle (Niggemann et al., 2005). APT 
has higher sensitivity than SPT test for food allergy in young children with AD, and can be 
used to supplement the SPT in diagnosing food allergy in AD children(Stromberg, 2002) and 
those with late reactions were more easily to have positive APT tests to the relevant foods 
(Saarinen et al., 2001).The combination of APT, SPT and serum-specific IgE reduce the need 
for oral food challenges in children with AD (Roehr et al., 2001) and significantly enhance 
the accuracy in the diagnosis of food allergy when the total IgE is normal or SPT is 
negative(Boissieu&Dupont,2003). APT test may also help among children with AD to 
prevent unnecessary restrictive diets (Niggemann et al., 2000).While in a study of allergy to 
cow's milk and hen's egg in 3 year- old children, no hypersensitivity to cow's milk or hen's 
egg was predicted by APT alone. The real value of the APT in food allergy in children need 
to be further studied(Osterballe et al., 2004).  
The sensitivity and specificity of the SPT of food allergen was 58% and 70%, while the 
sensitivity and specificity of the APT for late-phase clinical reactions of food allergen was 
76% and 95% respectively (Niggemann et al., 2000). The negative predictive value is over 
95%, while the positive predictive value is less than 40% of SPT (Sampson, 2003).So, a 
positive skin test cannot completely confirm a clinical food hypersensitivity, while a 
negative result can virtually rules out some kind of IgE-mediated food allergy. It should be 
noted that SPT may remain positive for many years after the loss of clinical food allergic 
reactivity. Patients should be re-challenged at intervals to determine whether their food 
allergy persists (egg, every 2–3 years; milk, soy, wheat, peanut, nuts, fish, and shellfish, 
every 1–2 years) (Sampson, 2001).  
2.3.2 Biomarkers in serum or other body fluid 
Seeking biomarkers in serum or other body fluid to reflect the severity of AD is an 
interesting topic. Though the fact that serum IgE level is elevated in more than half of AD 
has been well established, its correlation with disease severity is disputed, so was the 
interpretation for peripheral blood eosinophil count, which could be affected by many 
other factors except for hypersensitivity, such as parasite, drugs, hormone. There were 
reports that urine eosinophil protein X (Jenerowicz et al., 2006) and leukotriene E4 (Hon et 
al., 2004) may be used as biomarkers to reflect the severity of AD. Recently, Urinary 
aquaporin-2 was found to positively correlate with skin dryness of infant AD (Di et al., 
2010). The clinical manifestations and distribution pattern of AD may vary at different 
age-related stages. AD is most prevalent in infants. An objective, easy and non-invasive 
test for evaluation of infant AD and corresponding management is much expected by 
both healthcare workers and parents. 
2.3.2.1 Serum total IgE, specific IgE and IgE autoantibodies 
IgE and specific IgE (ELISA or Radioallergosorbent test/RAST) can be used without the 
need of preparing lesion-free skin and waiting-up of antihistamines drug withdrawal, it is 
more practical than SPT for the screening of food allergies in most office settings due to its 
quick and easy- to operate merit. Serum IgE levels are increased in about 80% of adult AD 
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(C.A.Akdis et al., 2006). The remaining 20%–30% of patients exhibiting normal serum IgE 
levels and lack allergen-specific sensitization, are classified as intrinsic AD (IAD) (Novak 
&Bieber, 2003; Boguniewicz et al., 2006). 28% of AD serum contains IgE autoantibodies 
which target keratinocytes in AD patients (Altrichter et al., 2008).  
For the total IgE and specific IgE, similar to skin tests, a negative result is fairly reliable in 
ruling out an IgE-mediated reaction. For a positive result, although the lesions significantly 
regress, there maybe no parallel decrease of serum IgE level. Further large-scale 
investigations of serum IgE levels between patients with extrinsic atopic dermatitis and 
intrinsic atopic dermatitis are needed (Ott et al., 2009). 
2.3.2.2 Mast cell, eosinophil and its cellular contents 
Mast cells play a very important role in the pathogenesis of AD. Tryptase and chymase are 
the major compound of mast cell granules. They have various effects on angiotensin, 
metalloproteases, lipoproteins, procollagen, neuropeptides and cytokines. The study by 
Badertscher et al confirmed that mast cell chymase is increased in chronic atopic dermatitis 
lesion (Badertscher et al., 2005), while there was no correlation of serum tryptase level with 
the severity of AD (Gerdes et al., 2009). 
Eosinophils play an important role in inflammatory process of AD, the activated eosinophils 
release granule proteins including eosinophil cationic protein (ECP) and eosinophil derived 
neurotoxin/eosinophil protein X (EDN/EPX). ECP is released from activated eosinophils 
during the inflammation process. Serum ECP level increased in children with AD 
(Badertscher et al., 2005; Damps-Konstanska et al., 2005), but there was no correlation with 
the SCORAD index (Wu et al., 2011). While a study by Selnes et al suggest that there is no 
association between serum ECP and AD in an unselected population of children (Selnes 
&Dotterud,2005).Several investigative evidence indicate that serum EDN may reflect the 
disease severity in childhood phase AD(Taniuchi et al., 2001; Lee et al.,2009) and correlated 
with SCORAD index (K.Y.Lee et al.,2009). 
2.3.2.3 T Lymphocytes and their subsets in peripheral blood 
For a long time, two main types of effector CD4+ T cells, named as type 1 T helper (Th1) 
and type 2 Th (Th2) respectively, have been thought to be deeply involved in AD. Th2 
cells produce IL-4, IL-5 and IL-13, Th1 cells produce interferon (IFN)-γ as the main 
cytokines. AD is an inflammatory skin disease characterized by the predominant 
infiltration of T cells, eosinophils, mast cell, dendric cell (DC) and macrophages in lesions. 
Disequilibrium between Th1/Th2 lymphocytes is an important feature of AD. Typically, 
AD has been considered the paradigm of a Th2–mediated disease, characterized by 
increase of Th2 and decrease of Th1 and their cytokines level in peripheral blood. 
Recently, research efforts have resulted in new subgroups of CD4+ T cells, such as IL-17–
producing Th cells (Th17), the main cytokine they produce is IL-17A, and T-regulatory 
(Treg) ( Agrawal et al., 2011; Souwer er al., 2010). There are two main groups of Treg cells 
identified. One is the natural Treg cells, characterized by CD4+CD25+ phenotype and 
develops under the control of the transcription factor FoxP3. The other is the adaptive 
Treg or T-regulatory type 1 (Tr1), characterized by the secretion of high levels of IL-10(M. 
Akdis et al., 2004; C.A.Akdis et al., 1998). It is suggested that the onset of allergic diseases 
are partly caused by insufficient development of allergen-specific Tregs. FoxP3+Treg 
could be found in the perivascular, dermis interstitial, and the dermoepidermal junction 
and the basal and suprabasal epidermal layers of AD (Caproni et al., 2007). But the study 
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by Hayashida et al indicated that FoxP3+Treg subsets was similar to that of normal 
controls in peripheral blood of the acute phase AD and the decreased number of 
circulating Th17 cells is negatively correlated with CCL17, IgE and eosinophil levels in 
AD patients (Hayashida et al., 2011). IL-17 has been identified in acute AD lesions (Toda 
et al., 2003). The exact role of Treg and Th17 cell in AD is still unclear. 
2.3.2.4 Cytokines and chemokine in the serum 
A complex network of cytokines and chemokines are involved in atopic inflammation, at 
both the starting and maintainance stages of the inflammation. Scratching injury induce the 
production of proinflammatory cytokines (such as IL-1, TNF-α, GM-CSF), which in turn 
induce CCL27 and CCL17 development. Subsequently, CCL27 and CCL17 recruit skin-
homing memory T cells into the skin. Within the skin, T cells are activated and release 
effector cytokines (eg, IL-4, IL-5, IL-13 in acute phase lesion, or IFN-r in the chronic lesion of 
AD ).These effector cytokines will sustain and amplify the production of chemokines within 
atopic skin. In this complex procedure, many chemokines, (such as CCL1, CCL2, CCL11, 
CCL13, CCL18, CCL20, CCL21, and CCL26) interact with various immune effector cells 
through their receptors(D.Y.Leung et al., 2004; Homey et al., 2006). AD is a disease with the 
participation of whole body immune system, and that the immunologic abnormality is not 
limited to the skin. Generally, as is widely accepted that AD has been considered the 
paradigm of a Th2–mediated disease, characterized by increase Th2 and decrease Th1 and 
cytokines level, elevated serum IgE levels, eosinophilia in peripheral blood. Recent 
researched showed that the severity of AD has also been found to be associated with the 
levels of various other cytokines and chemokines in the lesion and serum, in addition to the 
conventional serum parameters, such as total serum IgE (tIgE), eosinophilic cationic protein 
(ECP), increased T helper type 2 (Th2)-skewed cytokine patterns(IL4,13) and decreased IFN-
γ. Some of them in the serum of AD are correlated with disease severity, and thus may be 
new biomarkers to reflect AD disease severity. Clinical trials on interleukins and 
chemokines in the serum of patients with AD were summarized, in table1 and table 2. 
Interleukin/IL  
Many interleukins participate in AD and it is a consensus that increased IL4, 13 levels are 
seen in the serum of AD. Recently, many of other interleukins have been shown to play roles 
in the pathogenesis of AD, and increased serum levels have been detected (in table1). IL-10 
is a powerful Th2 cytokines produced by LC in the lesion of AD and exerts its function 
through inhibition of the secretion of Th1 cytokines. While, the level of IL-10 in the serum 
may be not a significant marker (Shin et al., 2005). IL-22, a member of the IL-10 family and 
known to be preferentially produced by Th17 cells, is increased and has significant 
correlation with CCL17 levels in the serum of AD patients (Hayashida et al., 2011). On the 
contrary, IL-12 is prominently expressed in the chronic lesion of AD, it is a powerful inducer 
of Th0 to Th1 conversion and subsequent IFN-γ secretion from Th1.The level of IL-12 in the 
serum of AD is controversially reported. Piancatelli et al confirmed the serum IL-12 levels 
increased in paediatric AD (Piancatelli et al., 2008), while the study by Aral, M et al showed 
that there was no statistically significant difference between children AD and controls in 
respect of serum levels of IL-12(Aral et al., 2006). IL-16 is a natural ligand of CD4 molecules. 
Besides its chemotactic properties to CD4-expressing cells, IL-16 amplifies inflammatory 
processes and possesses immunoregulatory functions (Mathy et al., 2000; Nagy et al., 2011). 
IL-16 was found to be increased in the serum of AD, both in child and adult patients (Nagy 
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et al., 2011; Belloni Fortina et al., 2006; Masuda et al., 2003).Also ,the level of IL-16 in the 
serum was significantly correlated with serum total IgE(Nagy et al., 2011), but not correlated 
with SCORAD index(Belloni Fortina et al., 2006) and eosinophils counting in peripheral 
blood(Nagy et al., 2011).The finding of Masuda K. et al confirmed IL-16 level in serum was 
significantly higher in patients with AD, and decreased significantly after topical treatment 
with corticosteroids or tacrolimus (Masuda et al., 2003). IL-18 is a pleiotropic cytokine that 
works both in Th1 and Th2 lymphocyte-mediated immunity. As a member of the IL-1 super 
family, IL-18 is a potent inducer of IFN-γ. IL-18 is involved in the pathogenesis of AD 
including Th1 and Th2 T lymphocyte-mediated immunity, including cytokine accumulation, 
and increase of IgE and histamine levels. Increased serum level of IL-18 and correlation with 
disease severity, eosinophil counts and serum sIL-2R levels was reported in several 
researches both in adult and children patients (Aral et al., 2006; Yoshizawa et al., 2002; Park 
&Youn, 2007; Sohn et al., 2004; Hon et al., 2004). IL-31 is a Th derived cytokine. Serum IL-31 
was found over-expressed in both adults and paediatric AD and its serum level correlated 
positively with the disease severity (Raap et al., 2008; Ezzat et al., 2011). 
Chemokines their receptors 
Little is known about the very early events of atopic skin inflammation. The unceasing 
amplification inflammation cycle in AD lesions might start with pruritus and the injury 
induced by scratching, and skin barrier disruption, resulting in proinflammatory cytokine  
 
Interle-
ukins 
Correlation with other 
clinical parameters 
References 
Expression in 
serum 
Age of studied 
populations 
IL-2 
Inverse correlation with 
serum IgE 
Yoshizawa  
et al., 2002 
Increase 
Adult  
(13–43years) 
IL-12 
Negative correlation with 
age and positive with 
SCORAD index 
Piancatelli  
et al., 2008 
Increase 
Paediatric AD 
(1-184months) 
 
Positive correlation with 
SCORAD 
Aral et al., 
2006 
No different 
with controls. 
5–12 year old 
 
Positive correlation with  
IL-10 
Yoshizawa  
et al., 2002 
Increase 
Adult 
(13–43years) 
IL-16 
Positive correlation with 
serum total IgE 
Nagy et al., 
2011 
Increase 
Mean :18.6 years; 
range: 7–49 years 
 
No correlation with 
SCORAD index 
Belloni 
Fortina et al., 
2006 
Increase Children 
 
Positive correlation with 
eosinophil count in 
peripheral blood and 
SCORAD 
Masuda et al., 
2003 
Increase 
Adult:  
aged 14 – 52 years, 
median 22 
IL-18 Not done 
Narbutt et al., 
2009 
Decrease under 
10 years, no 
difference over 
10 years 
Mean age 11.4 
years with 
moderate AD 
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Interle-
ukins 
Correlation with other 
clinical parameters 
References 
Expression in 
serum 
Age of studied 
populations 
 
Positive correlation with 
SCORAD index 
Park et al., 
2007 
Increase 
15±10 years; 
range:2-41years  
 
Positive correlation with 
SCORAD index  
Aral et al., 
2006 
Increase 5–12 year old 
 
Higher in sever AD than in 
mild AD 
Sohn et al., 
2004 
Increase 
Age range,  
9 months to 11 
years; mean, 4.28± 
2.8 years 
 
Positive correlation with 
SCORAD index 
Hon et al., 
2004 
Increase 
Median age of  
2.2 years 
(interquartile 
range 0.7-4.6 
years) 
 
Positive correlation with 
eosinophil counts and serum 
soluble IL-2 receptor  
Yoshizawa  
et al., 2002 
Increase 
Adult  
(13–43years) 
IL-22 
Positive correlation with 
CCL17 
Hayashida  
et al., 2011 
Increase 
Adults (mean±SD 
age;27.2±6.1 years ) 
IL-31 
Positive correlation with 
LSS, SSS and SCORAD 
index 
Ezzat et al., 
2011 
Increase 
Ages ranged 
between 1 and 10 
years (mean ± SD: 
5.75 ± 2.11 years)  
 
Positive correlation with 
SCORAD index both in 
extrinsic AD and intrinsic 
AD 
Raap et al., 
2008 
Increase 
Extrinsic AD 
(mean age, 
37.8±14.1 years); 
Intrinsic AD 
(mean age, 
31.8±11.2 years) 
Table 1. Literatures about serum interleukins in AD 
 
Chemo-
kine 
Correlation with other 
clinical parameters 
References 
Expressions in 
serum 
Adult / childhood 
/infant phase 
CXCL9 Not done 
Narbutt et al., 
2009 
Decrease under 
10 years old 
Children (mean 
age 11.4 years 
with moderate AD 
CXCL10/
IP-10 
Not done 
Narbutt et al., 
2009 
Decrease under 
10 years old  
Children (mean 
age 11.4 years 
with moderate AD 
 
Did not correlate with 
SCORAD index and its 
extend and intensity  
T.F.Leung  
et al., 2003 
No difference 
between mild 
and moderate 
AD 
Median 2.1 years, 
range 0.6-4.2 years 
www.intechopen.com
 Atopic Dermatitis – Disease Etiology and Clinical Management 
 
178 
Chemo-
kine 
Correlation with other 
clinical parameters 
References 
Expressions in 
serum 
Adult / childhood 
/infant phase 
CXCL12 Not done 
Narbutt et al., 
2009 
Increase Children 
CCL2 
/MCP-1 
Did not correlate with 
SCORAD index and its 
extend and intensity  
T.F.Leung  
et al., 2003 
No difference 
between mild 
and moderate 
AD 
Median 2.1 years, 
range 0.6-4.2 years 
CCL11 
/eotaxin
/EOX 
no significant relationship 
with TARC, MDC, IgE or 
SCORAD index 
Jahnz-Rozyk 
et al., 2005 
Increase 
Age: Mean±SD of 
24.7±10.7 years  
 
Positive correlate with 
SCORAD extent, but not 
SCORAD index. 
T.F.Leung  
et al., 2003 
Higher in 
moderate AD 
than in mild 
AD  
Median 2.1 years, 
range 0.6-4.2 years 
CCL17 
/TARC 
Positive correlation with 
soluble HLA-G. High 
umbilical cord serum levels 
were associated with 
infantile AD development 
Miyahara  
et al., 2011 
Umbilical cord 
serum levels 
from neonates 
destined to 
develop AD in 
infancy were 
higher than in 
those from 
neonates who 
showed no 
signs of AD 
during infancy; 
Serum levels 
were higher in 
mothers with 
AD than in 
those without 
AD.  
Neonates and 
their mothers 
 Not done 
Narbutt et al., 
2009 
Decrease under 
10 years old, 
increase over 10 
years old  
Children  
(mean age 11.4 
years with 
moderate AD) 
 
Positive correlation with 
SCORAD index 
Nakazato  
et al., 2008 
Increase 
Infants (mean age 
4.5 months) 
 
Positive correlation with obj-
SCORAD index, peripheral 
blood eosinophil counts and 
serum immunoglobulin E 
Mostafa et al., 
2008 
Increase 
Children  
(ages ranged 
between 2 and 10 
years with a  
mean age of  
5 ± 2.8 years)  
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Chemo-
kine 
Correlation with other 
clinical parameters 
References 
Expressions in 
serum 
Adult / childhood 
/infant phase 
 
Positive correlation with 
SCORAD index  
Hon et al., 
2007 
Increase 
Aged younger 
than 18 years 
(mean ±SD:  
10.7 ± 4.4 years) 
 
Positive correlation with 
serum CTACK and SCORAD
index; decreased in 
accordance with ages 
Song et al., 
2006 
Increase 
Children  
(4.9±3.3 years,  
2 months to  
14 years) 
 
Positive correlation with 
SCORAD index 
Jahnz-Rozyk 
et al., 2005 
Increase 
Age (Mean±SD of 
24.7±10.7 years) 
 
Positive correlation with 
SCORAD extent and 
intensity components, 
Positive correlation with 
CCL22, but not SCORAD 
index
T.F.Leung  
et al., 2003 
No different 
between mild 
and moderate 
AD 
Median 2.1 years 
range 0.6-4.2 years 
 
Correlation with eosinophil 
number, SCORAD index, 
serum sE-selectin and 
weakly correlated with 
serum sIL-2 receptor  
Kakinuma  
et al., 2001 
Increase 
Mean age ± SEM: 
26.6 ± 8.9 years 
CCL22 
/MDC 
Not done 
Narbutt et al., 
2009 
Increase over 
10 years old  
Children (mean 
age 11.4 years 
with moderate AD 
 
Positive correlation with 
SCORAD index 
Nakazato  
et al., 2008 
Increase 
Infants (mean age 
4.5 months) 
 
Positive correlation with obj-
SCORAD index, peripheral 
blood eosinophil counts and 
serum immunoglobulin E 
Mostafa et al., 
2008 
Increase 
Children 
(ages ranged 
between 2 and 10 
years with a mean 
age of 5 ± 2.8 
years)  
 
Positive correlation with 
SCORAD index 
Jahnz-Rozyk 
et al., 2005 
Increase 
Age: Mean±SD of 
24.7±10.7 years 
 
Positive correlation with 
SCORAD index and its 
extent and intensity 
components, Positive 
correlation with CCL17
T.F.Leung  
et al., 2003 
Higher in 
moderate AD 
than in mild 
AD  
Median 2.1 years 
range 0.6-4.2 years 
 
Positively related with 
SCORAD index, serum sE-
selectin, sIL-2R, TARC and 
eosinophil numbers in 
peripheral blood 
Kakinuma  
et al., 2002 
Increase Not described  
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Chemo-
kine 
Correlation with other 
clinical parameters 
References 
Expressions in 
serum 
Adult / childhood 
/infant phase 
CCL26 
/eotaxin-
3 
Positive correlation with the 
serum CCL17 ,CCL22 levels, 
eosinophil numbers in 
peripheral blood and 
SCORAD index 
Kagami et al., 
2003 
Increase 
Adult (mean±SD: 
28·7±7·1 years）  
CCL27 
/CTACK 
Not done 
Narbutt et al., 
2009 
Increase under 
10 years old 
Children (mean 
age 11.4 years 
with moderate AD 
 
Positive correlation with 
SCORAD index 
Nakazato  
et al., 2008 
Increase 
Infants (mean age 
4.5 months) 
 
Positive correlation with 
SCORAD index 
Hon et al., 
2007 
Increase 
Aged younger 
than 18 years 
(mean ±SD:  
10.7 ± 4.4) 
 
Positive correlation with 
their serum TARC; SCORAD 
index; decreased in 
accordance with their ages 
Song et al., 
2006 
Increase 
Children:  
4.9±3.3 years,  
2 months to  
14 years 
 
Positive correlated with 
SCORAD index 
Hon et al., 
2004 
Increase 
Children: median 
age of 5 (range:  
1–11 years) 
 
Positive correlation with 
SCORAD index, sIL-2 
receptor, sE-selectin,TARC, 
MDC in serum
Kakinuma  
et al., 2003 
Increase 
Adult(mean ± 
SEM age,  
28.5 ± 6.8 years)  
CCL28/ 
MEC 
Positive correlation with LSS 
and SCORAD index, 
peripheral eosinophil counts, 
and serum LDH  
Ezzat et al., 
2009 
Increase 
Ages ranged 
between 8 and 120 
months  
(mean ± SD: 47 ± 
22 months) 
 Not done 
Kagami et al., 
2005 
Increase 
Adults(mean±SD: 
28.7± 6.7 years)  
CX3CL1 
/fracta-
lkine 
Positively associated with 
the scoring system proposed 
by Rajka and Langeland. 
Echigo et al., 
2004 
Increase 
Age: 24.7 ± 7.4 
years 
Table 2. Literatures about serum chemokines in AD. Abbreviations used in the table: 
CXCL10/IP-10, IFN-induced protein of 10 kd; CCL2/MCP-1, monocyte chemotactic protein 
1; CCL11 /eotaxin (EOX); CCL17/TARC, thymus and activation-regulated chemokine; 
CCL22/MDC, macrophage-derived chemokine; CCL26/eotaxin-3; CCL27/CTACK, 
cutaneous T cell–attracting chemokine; CCL28/MEC, Mucosa-associated epithelial 
chemokine; CX3CL1/fractalkine; sE-selectin, serum soluble E-selectin; sIL-2R, soluble 
interleukin-2 receptor. 
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and chemokine production, directing the recruitment of pathogenic leukocytes to the skin 
(Steinhoff et al., 2006). There are many researches conformed that they are useful inflammatory 
markers for assessing severity of AD. Chemokines attract leukocytes transmigrate into the skin 
in AD by their gradients directing. Chemokine ligand-receptor interactions direct the 
multistep process of leukocyte migration. Chemokines can be classed into 4 subclasses 
according to the arrangement of N-terminal cysteine residues: CXC chemokines (CXCL); CC 
chemokines (CCL); C chemokines (XCL), and CX3C chemokine (CX3CL). To date, 45 human 
chemokine ligands and 10 CC chemokine, 7 CXC chemokine, 1 CX3C, and 1 XC receptors have 
been identified (Rossi & Zlotnik, 2000; Zlotnik &Yoshie, 2000; Balabanian et al., 2005). Many 
chemokines, including CCL1, CCL2, CCL3, CCL4, CCL5, CCL10, CCL11, CCL13, 
CCL17，CCL18, CCL20, CCL22, CCL26, CCL27, CCL28, CX3CL1，CXCL9, 
CXCL10，CXCL12，have been presumed to be involving in AD phenotype (Homey et al., 
2006; Toda et al., 2003; Hayashida et al., 2011; Piancatelli et al., 2008; Jahnz-Rozyk et al., 2005; 
T.F.Leung et al., 2003; Miyahara et al., 2011; Hon et al., 2004,2007; Kagami et al., 2003,2005; 
Yoshizawa et al., 2002; Park&Youn, 2007; Kakinuma et al; 2003; Ezzat &Shaheen, 2009; Echigo 
et al., 2004) (in table2). These researches indicated that the imbalance in serum concentration of 
Th-1- and Th-2-derived chemokines may be one of the factors involved in pathogenesis of AD 
and biomarkers of AD disease severity. 
CXCL9, CXCL10, and CXCL11 are Th-1-derived chemokines, while CCL11, CCL17, CCL22, 
CCL27 are Th-2-derived chemokines, leading to preferential influx of T1/Th2 lymphocytes 
to the lesion of AD respectively (Narbutt et al., 2009). CCL28 is recently identified to be 
selectively expressed by keratinocytes and its functional ligands are CCR3 and CCR10. 
CCL28 is similar to CCL27 in human, they shares 40% amino acid identity(Hieshima et al., 
2003). CCL26, CCL11 through CCR3 contribute to eosinophils recruitment to the lesion of 
AD(Homey et al., 2006). CX3CL1 originates from the endothelial cell and its receptor is 
CX3CR1, which can direct several kinds of immunological effective cells (such as T cell, NK 
cell and monocytes and DC) (Echigo et al., 2004).  
Research by Narbutt J et al indicated that the serum level of CXCL9 and CXCL10 was 
decreased in childhood AD (Narbutt et al., 2009). While there were many study indicating 
that CCL11, CCL17, CCL22, CCL27 level in the serum were increased in AD patients and 
correlated with disease severity (T.F.Leung et al., 2003; Mostafa et al., 2008; Nagy et al., 2011; 
Song et al., 2006; Sohn et al., 2004; Kakinuma et al., 2002,2008; Jahnz-Rozyk et al., 2005; 
Hijnen et al., 2004; Kakinuma et al., 2001). Among the Th2 chemokines, serum CCL27 
correlated most significantly with the severity of AD (Nakazato et al., 2008).The research by 
Miyahara et al showed that increased level of CCL17 in umbilical cord serum of neonates 
destined to develop AD in infancy (Miyahara et al., 2011).But another research indicated 
that the serum level of CCL17 and IL-18 were decreased, and CXCL12 and CCL27 increased 
in kids younger than 10 years old. In childhood AD of over 10 years old, serum 
concentration of CXCL12, CCL17, CCL22 was higher (Toda et al., 2003).There are many 
research results confirmed that the increased CCL28 level in the serum of AD patients and 
correlated positively to the severity scores (Jahnz-Rozyk et al., 2005; T.F. Leung et al., 2003; 
Ezzat &Shaheen ,2009; Kagami et al., 2005; Ezzat et al., 2009), so CCL28 may be a useful 
parameter in the clinical diagnosis and prognosis after proper treatment. CCL26, as a 
chemokine attract eosinophils to the skin lesion is elevated in the serum and significantly 
correlated with the serum CCL17 and CCL22 levels, peripheral blood eosinophil numbers 
and SCORAD index (Kagami et al., 2003).  
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Taken together, interleukins and chemokines are important markers in AD. But the normal 
levels in infancy and age-specific analysis in atopic dermatitis of these markers have not 
been well determined, this should be taken into account when interpreting the results, 
especially in infant AD. 
Tumor necrosis factor(TNF) 
B cell-activating factor (BAFF) is a member of tumour necrosis factor superfamily. BAFF plays 
an important role in the survival and maturation of B lymphocyte cells. The level of serum 
BAFF in childhood AD patients increased and significantly correlated with total serum IgE 
level and total eosinophil count in peripheral blood(Jee et al., 2010).While , in another research, 
serum BAFF level was not elevated in patients with AD (Matsushita et al., 2008). 
Neurotrophins and neuropeptides,Growth factors and hormones 
The Neurotrophins (NT) family including Nerve growth factor (NGF), Brain-derived 
neurotrophic factor (BDNF), NT- 3,4,5, 6 and NT- 7 (Leibrock et al., 1989; Kolbeck et al., 1994). 
The biologic effects of NT family are not merely restricted to the central nervous system but 
also relevant to the nerve cells present in other organs including the skin. More and more 
studies have demonstrated that NTs play an important role in the pathogenesis of AD. 
Association of BDNF gene polymorphisms and the increased serum levels in AD patients was 
conformed. The level of BDNF in the serum was correlated with intrinsic type of AD severity 
(Ma et al.,2010; Raap et al., 2006).While the level of NGF in serum has no significant 
correlation with total IgE, or severity of disease assessed by SCORAD (Schulte-Herbruggen 
et al., 2007). Although serum levels of vasoactive intestinal peptide (VIP) are found to be 
increased in patients with AD, there was no correlation between serum VIP levels and 
disease severity, serum LDH levels, total serum IgE levels, and peripheral blood eosinophil 
counts in patients with AD (Umemoto er al., 2003). Also there was also no association 
between serum VIP concentration and itch intensity (C.H.Lee et al., 2006). A study showed 
TEWL, serum IgE and beta-endorphin were independent parameters for assessing itch 
intensity in AD (C.H.Lee et al., 2006). 
Mast cell in the lesions is thought to play an important role in the pathogenesis of AD. Stem 
cell factor (SCF), and the interaction of SCF and its receptor, KIT (tyrosine kinase 
transmembrane receptor) are the key factors that induce mast cell growth, migration and 
differentiation. Serum levels of soluble SCF and soluble KIT were significantly elevated in 
AD patients, positively correlated with the disease severity, and decreased after effective 
treatment with topical corticosteroids (Kanbe et al., 2001). 
Significantly higher expression of thymic stromal lymphopoietin (TSLP), an IL-7 – like 
cytokine, by lesional skin can induce DCs to express Th2 cell – polarizing signals in AD. DCs 
activated by TSLP can induce Th0 to differentiate into Th2 cells and play important roles in 
the maintenance and regulation of Th2 memory cells (Wang et al., 2006). While the serum 
TSLP level is inconsistent by different clinical study (E.B.Lee et al., 2010; Alysandratos et al., 
2010; Nakamura et al., 2008). 
The increasing level of serum antidiuretic hormone (ADH) in severe AD was confirmed , 
which was related with TEWL(Aoki, et al., 2005). 
2.3.2.5 Enzymes  
In the AD lesion, high lactate dehydrogenase(LDH) activity was found , especially in the 
epidermis. Also in the serum, the level of LDH and its isozyme (LDH4 and LDH5) is 
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increased. After recovery of the patients, the serum LDH activity tended to decline. But 
there are no correlation between the LDH level and eosinocyte count in the peripheral blood 
or serum IgE level (Morishima et al., 2010). 
Matrix metalloproteinases(MMPs) and their inhibitors, tissue inhibitors of metallopro-
teinases (TIMPs), are involved in inflammation mediated tissue destruction and remodeling. 
The maintenance of homeostasis of MMPs/TIMPs in the lesion is regulated by 
proinflammatory cytokines and growth factors (Woessner, 2001). In the study of Katoh N et 
al, they found that the level of TIMP-1 in the serum of AD patients was significantly 
increased, but reduced after treatments. The TIMP-1 level correlated with peripheral 
eosinophil counts, serum levels of IgE and LDH, eruption score, and eruption area. 
Moreover, the patients with chronic eruptions (lichenification and prurigo) had significantly 
higher TIMP-1 levels, while those with acute lesions were not correlated with TIMP-1 level 
in the serum. The authors gave a hypothesis that serum TIMP-1 level may be a useful 
marker to estimate the long-term disease activity of AD (Katoh et al., 2002).  
Human tissue kallikreins, or kallikrein-related peptidases (KLKs), are the largest family of 
trypsin- or chymotrypsin-like serine proteases (SPs). At least eight KLKs are expressed in 
normal skin, of which KLK8, KLK5, KLK7 have been reported to be the most important 
KLKs involved in maintenance of the homeostasis of normal epidermis by cleaving 
corneodesmosomes. Moreover, KLK5 and KLK14 activate protease-activated receptor 
(PAR)-2, which is a signaling receptor in epidermal inflammation and a regulator of 
epidermal barrier function (Meyer-Hoffert, 2009). In the lesion of AD, the level of KLKs 
were increased (Voegeli et al., 2009). In the serum of AD, KLK8 was reported significantly 
elevated, while KLK5 and KLK11 were significantly decreased (Komatsu et al., 2007). The 
different expression between lesion and serum may be due to the diversity of the origins of 
KLKs from many tissues and organs. 
Neopterin is biosynthesized from guanosine triphosphate and produced preferentially by 
monocytes and macrophages. Increased neopterin concentrations in serum or urine are 
connected with diseases linked with cellular immune reaction. Recently, serum neopterin 
levels was reported to increase and to be considered as a diagnostic marker of AD 
(Ciprandi et al., 2011).  
2.3.2.6 Soluble immune receptors (SIRs) 
The serum levels of SIRs ,such as sCD14, sCD23, sCD25 and sCD30 have been reported to be 
associated with AD (Ott et al., 2010; El Mongy et al., 2008; Di Lorenzo er al., 2003; Hon et al., 
2005; Furue et al., 1999). CD30 released by CD30+ cells, a member of the TNF receptor 
superfamily, is a costimulatory molecule expressed on activated T and B cells. After cell 
activation, its extracellular domain generates soluble CD30 (sCD30) by enzymatic cleavage. 
Serum sCD30 is regarded as a indicator of Th2-type immune responses (El Mongy et al., 2008). 
Although there were several researches indicated that serum sCD30 levels were significantly 
higher and correlated positively with the severity of AD as assessed by SCORAD, age and 
duration of the disease (El Mongy et al., 2008; Di Lorenzo et al., 2003). Ott H et al indicated 
that the serum level of sCD23, sCD25 and sCD30 were highly aged dependent and can not 
be regarded as useful biomarkers for assessment of childhood AD (Ott et al., 2010).  
2.3.2.7 Others in serum 
Serum immunoglobulin free light chains (FLC) is classically associated with monoclonal 
gammopathies. An significantly increased level of FLC was observed in severe AD , while 
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the association of FLC levels with age or total IgE levels was not confirmed (Kayserova et 
al., 2010).Vitamin D deficiency may be related to the severity of AD in the children patients. 
The level of serum in severe AD was significant lower than the mild AD (Peroni et al., 2010). 
2.3.3 Biomarkers in urine 
Leukotriene B4 (LTB4), LTC4, LTD4 and LTE4, the products of the oxidative metabolism of 
cell membrane arachidonic acid are secreted from eosinophils, mast cells and other 
inflammatory cells. As LTE4 is stable in urine, the urinal level of LTE4 may be a good 
marker for activation of mast cells and eosinophils in vivo. Urinary LTE4 increased in severe 
AD and correlated with severity of AD in children had been confirmed. Those having to 
sensitization to common allergens had higher LTE4 level than those without in the severe 
AD (Hon et al., 2004; Oymar &Aksnes, 2005). 
EDN/EPX, one of the major proinflammatory mediators released by activated eosinophils, 
can induce severe tissue damage and maintenance and exacerbation of AD. A positive 
correlation between the SCORAD and serum ECP and urine EPX levels has been reported in 
children and adult patients (Breuer et al., 2001; Pucci et al., 2005; Pucci et al., 2000; Goto et 
al., 2007),also correlated with visual analog scales (VAS) scores for itching(Goto et al., 2007). 
While urinary EDN concentrations did not correlate with the number of eosinophils in the 
peripheral blood (Goto et al., 2007). 
Urinary nitrate level significantly increased in AD patients. The severity and extent of AD 
significantly correlated with urinary nitrate and malondialdehyde level, but it did not 
correlate with urinary 8-hydroxydeoxyguanosine (8-OHdG) level (Nakai et al., 2009).  
The increased TEWL in AD is attributable partly to impaired barrier function of the skin. 
Remarkable loss of body fluid would induce a series of systemic regulatory reactions. The 
functional antidiuretic hormone (ADH)–aquaporin (AQP)-2 axis is a major regulatory 
system to keep water balance. Increased serum ADH was detected in severe AD, a result 
possibly due to a dehydrated state caused by increased TEWL in these patients (Aoki, 2005). 
Recently, Urinary aquaporin-2 was found to be increased in infant AD patients, and 
positively correlate with skin dryness of infant AD, but its concentrations did not correlate 
with the number of eosinophils in the peripheral blood and the total IgE level in serum and 
disease severity (Di et al., 2010).  
Increased neopterin levels in serum or urine are connected with diseases related with 
cellular immune reaction (Murr et al., 2002).In the association study by Horak E et al 
between neopterin in cord blood and urine in early childhood and the development of 
atopic dermatitisAD, they showed that family history of atopic disease was associated with 
lower urinary neopterin levels at age of 6 years (Horak er al., 2006). 
Prostaglandin D2 (PGD2), the major cyclooxygenase product of mast cells, is a good marker 
for mast cell activation. In the lung, PGD2 converts to 9a, 11b-prostaglandin F2 (9a,11b-
PGF2), which can be detected in the urine (O'Sullivan, 1999). The study of Oymar K and 
Aksnes L indicated that 9a, 11b-PGF2 level in the urine of severe childhood AD patients was 
increased and indicated that 9a, 11b-PGF2 may be a useful biomarker of mast cell activation 
in the urine (Oymar &Aksnes, 2004).  
3. Conclusions 
AD is a complex cutaneous disorder characterized by local and/or systemic immune 
reactions, and skin barrier dysfunction. Its clinical manifestations are affected by many 
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factors, such as gene, environment, race, age etc. Further studies should be performed to 
findings of definitive biomarkers to assess the disease severity and evaluation of treatment 
effects. But the normal levels in infancy and age-specific analysis in AD of these markers 
have not been well determined, this should be taken into account when interpreting the 
results, especially in infant AD. 
4. Abbreviations 
Atopic dermatitis (AD); 
Hanifin and Rajka diagnostic criteria (H-R criteria); 
International Study of Asthma and Allergies in Childhood (ISAAC); 
Quality of life (QoL); 
Scoring Atopic Dermatitis index (SCORAD); 
Dermatitis Area and Severity Index score (ADASIS); 
Eczema Area and Severity Index (EASI); 
Psoriasis area and severity index (PASI); 
Nottingham Eczema Severity Score (NESS); 
Children's Dermatology Life Quality Index (CDLQI); 
Objective severity assessment of atopic dermatitis (OSAAD system); 
Stratum corneum hydration (SCH); 
Trans-epidermal water loss (TEWL); 
Body surface area (BSA); 
Stratum corneum (SC); 
Natural moisturizing factors (NMF); 
Pyrrolidone carboxylic acid (PCA); 
Urocanic acid (UCA); 
Atopy patch test (APT); 
Skin prick test (SPT); 
Eosinophil cationic protein (ECP); 
Eosinophil derived neurotoxin/eosinophil protein X (EDN/EPX); 
T-regulatory (Treg); 
Interleukin (IL); 
CCL2/MCP-1, monocyte chemotactic protein 1;  
CCL11 /eotaxin (EOX); 
CCL17 /TARC, thymus and activation-regulated chemokine;  
CCL22 /MDC, macrophage-derived chemokine;  
CCL26 /eotaxin-3;  
CCL27/CTACK, cutaneous T cell–attracting chemokine; 
CCL28/ MEC, Mucosa-associated epithelial chemokine;  
CXCL10 /IP-10, IFN-induced protein of 10 kd;  
CX3CL1 /fractalkine;  
sE-selectin, serum soluble E-selectin ; 
sIL-2R, soluble interleukin-2 receptor . 
Tumor necrosis factor (TNF); 
B cell-activating factor (BAFF); 
Neurotrophins (NT); 
Nerve growth factor (NGF); 
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Brain-derived neurotrophic factor (BDNF); 
Vasoactive intestinal peptide (VIP); 
Stem cell factor (SCF); 
Tyrosine kinase transmembrane receptor (KIT); 
Thymic stromal lymphopoietin (TSLP); 
Dendric cell (DC); 
Antidiuretic hormone (ADH); 
Lactate dehydrogenase(LDH); 
Matrix metalloproteinases(MMPs); 
Tissue inhibitors of metalloproteinases (TIMPs); 
Kallikreins (KLKs); 
Soluble immune receptors (SIRs;) 
Free light chains (FLC); 
Leukotriene(LT); 
Visual analog scales (VAS); 
8-hydroxydeoxyguanosine (8-OHdG); 
Aquaporin (AQP); 
Prostaglandin D (PGD) 
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